**Table S1. EXC MO concentration efficacy validation**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | MOs Injected | Concentration Injected | Moribund (%) | Dead (%) | Viable (%) | n |
|  |  | EXC | 2 mM | 37.1 | 58.1 | 4.8 | 167 |
|  |  | EXC + p53 MO | 2 mM  | 38.7 | 57.1 | 4.2 | 168 |
|  |  | EXC | 1.4 mM | 61.9 | 32.1 | 6.0 | 168 |
|  |  | EXC + p53 MO | 1.4 mM  | 57.7 | 30.4 | 11.9 | 168 |
|  |  | EXC | 0.6 mM | 67.9 | 9.0 | 23.1 | 156 |
|  |  | EXC + p53 MO | 0.6 mM  | 56.4 | 14.7 | 28.8 | 156 |
|  |  |  |  |  |  |  |  |
|  |  | CTR | 2 mM  | 0.0 | 0.0 | 100.0 | 12 |
|  |  | CTR + p53 MO | 2 mM  | 16.7 | 0.0 | 83.3 | 12 |
|  |  | Non-injected |  | 2.1 | 2.1 | 95.8 | 48 |